Presidio Pharmaceuticals Obtains Rights to XTL Program

Presidio Pharmaceuticals, Inc. has entered into an agreement with XTL Biopharmaceuticals Ltd. for an exclusive, worldwide license to XTL’s proprietary HCV NS5A program.
The Earth Times